Tyme Inc.
Tyme Inc. is a clinical-stage biotechnology company developing novel cancer therapeutics, intended to be safe and effective across a broad range of tumor types. Our therapeutic intervention (SM-88) is designed to compromise cancer’s cellular defenses, exploiting its innate metabolic weaknesses, leading to cell death through oxidative stress and exposing cancer to the body’s natural immune system. SM-88 is currently in phase 2 trials with plans to broaden into several areas of cancer.